deoxypyridinoline has been researched along with HIV Coinfection in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piso, RJ; Rothen, JP; Rothen, M; Stahl, M | 1 |
| Bindi, G; de Martino, M; Galli, L; Galluzzi, F; Salti, R; Stagi, S | 1 |
| Kasahara, K; Konishi, M; Mikasa, K; Takahashi, K; Uno, K; Yoshimoto, E | 1 |
3 other study(ies) available for deoxypyridinoline and HIV Coinfection
| Article | Year |
|---|---|
Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used.
Topics: Alkaline Phosphatase; Amino Acids; Anti-HIV Agents; Bone and Bones; HIV Infections; Humans; Osteoporosis | 2011 |
Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I.
Topics: Amino Acids; Analysis of Variance; Body Mass Index; Bone Density; Case-Control Studies; Child; Child, Preschool; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Interleukin-6; Male; Osteocalcin | 2004 |
Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients.
Topics: Adult; Amino Acids; Antiretroviral Therapy, Highly Active; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Carrier Proteins; HIV Infections; Humans; Male; Membrane Glycoproteins; Osteoporosis; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B | 2005 |